Organogenesis Holdings (ORGO) Capital Expenditures Growth (3y) (2021 - 2026)
Organogenesis Holdings (ORGO) Capital Expenditures Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.39 Bn | 30.45 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 18.00 Bn | 16.69 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 28.56% |
| 10 | Organogenesis Holdings | 323.33 Mn | 231.23 Mn | 11.46 Mn | 16.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.57% |
| Dec 31, 2025 | -24.14% |
| Sep 30, 2025 | -40.11% |
| Jun 30, 2025 | -30.78% |
| Mar 31, 2025 | 24.72% |
| Dec 31, 2024 | -13.69% |
| Sep 30, 2024 | -46.42% |
| Jun 30, 2024 | -8.53% |
| Mar 31, 2024 | -45.87% |
| Dec 31, 2023 | -15.03% |
| Sep 30, 2023 | 48.51% |
| Jun 30, 2023 | -26.99% |
| Mar 31, 2023 | -22.36% |
| Dec 31, 2022 | 45.52% |
| Sep 30, 2022 | 101.31% |
| Jun 30, 2022 | 127.32% |
| Mar 31, 2022 | 80.66% |
| Dec 31, 2021 | 81.21% |
| Sep 30, 2021 | 161.13% |
| Jun 30, 2021 | 106.51% |